Cover Image
市場調查報告書

Synta Pharmaceuticals Corp.:產品平台分析

Synta Pharmaceuticals Corp. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224637
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
Synta Pharmaceuticals Corp.:產品平台分析 Synta Pharmaceuticals Corp. - Product Pipeline Review - 2015
出版日期: 2015年07月22日 內容資訊: 英文 52 Pages
簡介

Synta Pharmaceuticals Corp.是發明、開發、針對癌症及自體免疫疾病、慢性發炎等嚴重症狀之劃時代藥物並商品化的生物製藥公司。該公司的特徵是以獨家化合物庫為首,擁有綜合性的藥物研發方法論,以及臨床·前臨床階段的藥物候補之多元化開發平台。

本報告提供Synta Pharmaceuticals Corp.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Synta Pharmaceuticals Corp.的基本資料

  • Synta Pharmaceuticals Corp.概要
  • 主要資訊
  • 企業資料

Synta Pharmaceuticals Corp.:R&D概要

  • 主要的治療範圍

Synta Pharmaceuticals Corp.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Synta Pharmaceuticals Corp.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Synta Pharmaceuticals Corp.:藥物簡介

  • ganetespib
  • elesclomol
  • Small Molecule to Inhibit HSP90 for Inflammation
  • Small Molecules to Block CRACM Channel for Inflammation and Rheumatoid Arthritis
  • STA-128666
  • STA-129183
  • STA-2842
  • Small Molecule to Inhibit IL 12/IL 23 for Autoimmune Disorders and Inflammation

Synta Pharmaceuticals Corp.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Synta Pharmaceuticals Corp.:最近的開發平台趨勢

Synta Pharmaceuticals Corp.:暫停中的計劃

Synta Pharmaceuticals Corp.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • apilimod mesylate

Synta Pharmaceuticals Corp.:企業發表

Synta Pharmaceuticals Corp.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07279CDB

Summary

Global Markets Direct's, 'Synta Pharmaceuticals Corp. - Product Pipeline Review - 2015', provides an overview of the Synta Pharmaceuticals Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Synta Pharmaceuticals Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Synta Pharmaceuticals Corp. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Synta Pharmaceuticals Corp.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Synta Pharmaceuticals Corp.'s pipeline products

Reasons to buy

  • Evaluate Synta Pharmaceuticals Corp.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Synta Pharmaceuticals Corp. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Synta Pharmaceuticals Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Synta Pharmaceuticals Corp. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synta Pharmaceuticals Corp.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Synta Pharmaceuticals Corp. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Synta Pharmaceuticals Corp. Snapshot
    • Synta Pharmaceuticals Corp. Overview
    • Key Information
    • Key Facts
  • Synta Pharmaceuticals Corp. - Research and Development Overview
    • Key Therapeutic Areas
  • Synta Pharmaceuticals Corp. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Synta Pharmaceuticals Corp. - Pipeline Products Glance
    • Synta Pharmaceuticals Corp. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Synta Pharmaceuticals Corp. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Synta Pharmaceuticals Corp. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Synta Pharmaceuticals Corp. - Drug Profiles
    • ganetespib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • elesclomol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit HSP90 for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block CRACM Channel for Inflammation and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STA-128666
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STA-129183
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STA-2842
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit IL 12/IL 23 for Autoimmune Disorders and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Synta Pharmaceuticals Corp. - Pipeline Analysis
    • Synta Pharmaceuticals Corp. - Pipeline Products by Target
    • Synta Pharmaceuticals Corp. - Pipeline Products by Route of Administration
    • Synta Pharmaceuticals Corp. - Pipeline Products by Molecule Type
    • Synta Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action
  • Synta Pharmaceuticals Corp. - Recent Pipeline Updates
  • Synta Pharmaceuticals Corp. - Dormant Projects
  • Synta Pharmaceuticals Corp. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • apilimod mesylate
  • Synta Pharmaceuticals Corp. - Company Statement
  • Synta Pharmaceuticals Corp. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Synta Pharmaceuticals Corp., Key Information
  • Synta Pharmaceuticals Corp., Key Facts
  • Synta Pharmaceuticals Corp. - Pipeline by Indication, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015
  • Synta Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015
  • Synta Pharmaceuticals Corp. - Phase III, 2015
  • Synta Pharmaceuticals Corp. - Phase II, 2015
  • Synta Pharmaceuticals Corp. - Phase I, 2015
  • Synta Pharmaceuticals Corp. - Preclinical, 2015
  • Synta Pharmaceuticals Corp. - Discovery, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Target, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Route of Administration, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Molecule Type, 2015
  • Synta Pharmaceuticals Corp. - Pipeline Products by Mechanism of Action, 2015
  • Synta Pharmaceuticals Corp. - Recent Pipeline Updates, 2015
  • Synta Pharmaceuticals Corp. - Dormant Developmental Projects,2015
  • Synta Pharmaceuticals Corp. - Discontinued Pipeline Products, 2015
  • Synta Pharmaceuticals Corp., Other Locations
  • Synta Pharmaceuticals Corp., Subsidiaries

List of Figures

  • Synta Pharmaceuticals Corp. - Pipeline by Top 10 Indication, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Stage of Development, 2015
  • Synta Pharmaceuticals Corp. - Monotherapy Products in Pipeline, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Top 10 Target, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Top 10 Route of Administration, 2015
  • Synta Pharmaceuticals Corp. - Pipeline by Top 10 Molecule Type, 2015
  • Synta Pharmaceuticals Corp. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top